| AKESO |
AKESO |
92%
|
Pursuant to the terms of the License Agreement, Summit has final decision-making authority with respect to all of its commercialization activities including, but not limited to, commercial strategy, … |
| AKESO-INC |
AKESO-INC |
92%
|
Since in-licensing ivonescimab, from Akeso Inc. (Akeso, HKEX Code: 9926.HK) in January 2023, over 4,000 patients have been treated with ivonescimab in clinical studies globally, and over 70,000 patie… |
| GSK |
GSK plc |
90%
|
Reciprocal relationship from GSK graph: Reciprocal relationship from SMMT graph: Reciprocal relationship from GSK graph: Reciprocal relationship from SMMT graph: In January 2026, we announced a clini… |
| GSK |
GSK plc |
90%
|
In January 2026, we announced a clinical collaboration with GSK plc (GSK) to evaluate ivonescimab in combination with GSK's novel B7-H3, risvutatug rezetecan, in multiple solid tumors. |
| REVOLUTION-MEDICINES-INC |
REVOLUTION-MEDICINES-INC |
90%
|
In June 2025, we announced a clinical collaboration with Revolution Medicines, Inc. (RevMed) to evaluate ivonescimab in combination with three RAS(ON) inhibitors, including the multi-selective 3 inhi… |
| GORTEC |
GORTEC |
85%
|
In February 2026, we announced a clinical collaboration with GORTEC, a European Head and Neck Oncology and Radiotherapy Group based in France, to evaluate ivonescimab monotherapy and ivonescimab in c… |
| BNTX |
BioNTech SE |
72%
|
Reciprocal relationship from BNTX graph: Reciprocal relationship from SMMT graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from SMMT graph: Reciprocal relationship from BNTX g… |
| BNTX |
BioNTech SE |
72%
|
commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America, Middle East and Africa regions (collectively, the “Licensed Territory”). Akeso retained development and commercia… |
| CELG-RI |
CELG-RI |
72%
|
Reciprocal relationship from CELG-RI graph: Reciprocal relationship from SMMT graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from SMMT graph: Reciprocal relationship from … |
| CELG-RI |
CELG-RI |
72%
|
commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America, Middle East and Africa regions (collectively, the “Licensed Territory”). Akeso retained development and commercia… |
| JNJ |
Johnson & Johnson |
72%
|
Reciprocal relationship from JNJ graph: Reciprocal relationship from SMMT graph: commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America, Middle East and Africa regions (… |
| JNJ |
Johnson & Johnson |
72%
|
commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America, Middle East and Africa regions (collectively, the “Licensed Territory”). Akeso retained development and commercia… |
| MRK |
Merck & Co., Inc. |
72%
|
Reciprocal relationship from MRK graph: Reciprocal relationship from SMMT graph: commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America, Middle East and Africa regions (… |
| MRK |
Merck & Co., Inc. |
72%
|
commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America, Middle East and Africa regions (collectively, the “Licensed Territory”). Akeso retained development and commercia… |
